Article

Oncology on Canvas and The Hope Murals Project Reaches New York City

For the 10th anniversary of the Oncology on Canvas art competition, Lilly Oncology and the National Coalition for Cancer Survivorship created The Hope Murals Project, a traveling exhibit throughout the U.S.

For the 10th anniversary of the Oncology on Canvas art competition, Lilly Oncology and the National Coalition for Cancer Survivorship created The Hope Murals Project. The project allows anyone who has been affected by cancer to help paint a series of murals developed by artists who have previously submitted artwork to the competition. To date, the contest has had more than 4,500 applicants.

"This year, to celebrate the lives and the journeys and the stories that have been shared with us, we embarked on The Hope Murals Project," says Andrew Wiersma, of Lilly Oncology. "We are painting 10 murals in 10 cities across the United States and Puerto Rico." New York City marks the ninth stop of the tour, where the art exhibit and mural painting project were housed at Grand Central Terminal.

"We started the city tour earlier this year in Anaheim, Calif., at the Oncology Nursing Society convention at ONS, and we're going to end in two weeks in Tampa, Florida," Wiersma says. Beginning in 2015, hundreds of art submissions from this year's competition will begin touring the country at various hospitals, cancer centers and patient advocacy events.

[Watch "Oncology on Canvas Winner's Cancer Experience Shapes Her Artwork"]

Related Videos
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of woman with blonde hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Image of woman with black hair.
Image of man with black hair.
Related Content